Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

CanSino first with Phase II COVID-19 vaccine results, but one shot might not be enough, says GlobalData

Following the news that Chinese biotech CanSino published Phase II results of its COVID-19 vaccine candidate Ad5-nCoV; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offers his view: “With one dose, CanSino’s human adenovirus vector-based vaccine elicited receptor-binding and neutralizing antibodies in 508 patients peaking after 28 days. […]
Read more

AstraZeneca/Oxford University’s vaccine shows solid safety results in Phase I/II in increasingly crowded field of vaccine candidates, says GlobalData

Following the news that AstraZeneca and Oxford University published Phase I/II results of their COVID-19 vaccine candidate ChAdOx1/AZD1222; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst and Michael Breen, PhD, Director of Infectious Diseases at GlobalData, a leading data and analytics company, offer their view: Rosenbaum commented “The vaccine developed by Oxford University in collaboration with […]
Read more

CSAs have been disrupted by COVID-19

The COVID-19 pandemic has caused some disruptions in Contract Manufacturing Service Agreements (CSAs), says GlobalData, a leading data and analytics company. Johanna Swanson, Product Manager at GlobalData, comments: “For 2018 to 2019, oncology was the most common therapy area for a drug CSA, followed by central nervous system and infectious disease therapies. The greatest proportion […]
Read more

Tremfya’s approval could signal new era in PsA

Janssen, a subsidiary of Johnson and Johnson (J&J), recently announced that Tremfya (guselkumab) received Food and Drug Administration (FDA) approval for patients with active psoriatic arthritis (PsA). Despite being launched in a fairly mature market, if J&J is able to contract aggressively with pharmacy benefit managers, leading data and analytics company GlobalData expects that Tremfya […]
Read more

Giving in to governmental pressure and approving sub-par vaccine may dissuade further innovation, says GlobalData

There are indications that some companies may be expediting the approval of COVID-19 vaccines, sometimes with subpar effectiveness, in response to pressure from governmental organizations. The approval of such vaccines may display short-term benefits, however, it will dissuade other companies and institutes from developing more effective vaccines if a significant proportion of the population has […]
Read more

Prioritized rollout required for COVID-19 vaccine to achieve 75% population vaccinated for herd immunity to be effective, says GlobalData

As a vaccine product passes through clinical development, manufacturers will have to ensure that they are taking the required steps to ramp up production, as there is unprecedented global demand. The quick manufacture and distribution of effective vaccine products are vital, as a slow or botched rollout may lead to global unrest due to the […]
Read more

Truvada likely to be preferred HIV prevention drug despite cabotegravir’s superiority

Following the results of a Phase IIb/III trial that showed GSK’s investigational HIV prevention drug cabotegravir had superior efficacy over Gilead’s Truvada; Arafa Salam, PhD, Infectious Diseases Analyst at GlobalData, a leading data and analytics, company offers her view: “Although cabotegravir may be more effective than Truvada, cabotegravir has potential high costs. Moreover, there are […]
Read more

India’s first indigenous biologic, Biocon’s ALZUMAb gets approval for COVID-19 treatment, says GlobalData

Following the news that India-based biopharma company Biocon’s plaque psoriasis drug itolizumab (ALZUMAb) has secured approval from the Drugs Controller General of India (DCGI) for emergency use in COVID-19 patients; Nag Madhavi, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “ALZUMAb is a novel humanized anti-CD6 monoclonal antibody, which was […]
Read more

Eli Lilly’s and Regeneron’s COVID-19 mAbs spark interest as monotherapies along with potential as cocktails for treatment and post-exposure prevention, says GlobalData

COVID-19 research and development (R&D) has started to see the first set of novel drug candidates enter clinical trials by way of monoclonal antibodies (mAbs). Experts interviewed by GlobalData see potential in these but are cautious that the cocktail strategy may not pan out better than treating with a single mAb, according to reporting from […]
Read more

Emerging technologies highly impacting management of COVID-19 outbreak

COVID-19 has had a catalytic effect on emerging technologies and has pushed several technologies into the forefront of methods to manage the pandemic. This is likely to be a watershed event and it is expected that these new technologies will continue to be used as tools to handle any future pandemics or crises, says GlobalData, a leading data and analytics company. Health agencies and governments are […]
Read more

Significant unmet needs remain in idiopathic pulmonary fibrosis despite recent advancements

Despite recent advances in idiopathic pulmonary fibrosis (IPF), significant unmet needs remain including increased earlier diagnosis, improved drug safety and efficacy, improvement in patient quality of life and treatments for patients with severe disease, according to GlobalData, a leading data and analytics company. Tiffany Chan, Immunology Analyst at GlobalData, explains: “There are a number of […]
Read more
1 … 84 85 86 87 88 … 108